SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

Sophie Porret

Principal Scientist

Sophie is responsible for the upstream and downstream development of our lead vaccine candidate to combat human cytomegalovirus (CMV) and is overseeing its transfer to pre-clinical process development.

She started her career in industry as a scientist in early-stage research into protein expression and purification at a French start-up company PX’Therapeutics. Moving to UCB in Brussels she focused on operational and analytical support for manufacturing biological drugs for human use. She joined SpyBiotech in August 2017 from the UK division of UCB where she specialized in executing process understanding and optimization for drugs approaching Phase III clinical studies.

Sophie received her Master's Degree in Immunology, Infectious disease and Microbiology from the Joseph Fourier University of Grenoble, France.

Back to team

Read more about our pipeline and the diseases we are working to eradicate.

Our Pipeline